Volume 31, Issue 146 (May & June 2023)                   J Adv Med Biomed Res 2023, 31(146): 255-260 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Najari F, Setayesh A, Gopinath E, Mirzaei S. Evaluation of the Adverse Effects of Monoclonal Antibodies in Breast Cancer Treatment in a Tertiary Care Hospital in Bengaluru, India, in 2020. J Adv Med Biomed Res 2023; 31 (146) :255-260
URL: http://journal.zums.ac.ir/article-1-6902-en.html
1- Dept. of Legal Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran , najari.hospital@sbmu.ac.ir
2- Dept. of Pharmacy Practice, T. John College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka, India
3- Dept. of Legal Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (2749 Views)

Background and Objective: Breast cancer (BC) is the leading cause of cancer mortality among women in different countries around the world, including India. Monoclonal antibodies (MoAbs) have emerged as a promising targeted treatment for BC, improving the survival rate of these patients with minimum adverse effects. This study aimed to investigate the severity of the adverse effects of MoAbs in an Indian population.
Materials and Methods: This longitudinal descriptive study was conducted on 120 BC patients over six months in a tertiary care hospital in Bangalore, India, in 2020. A data collection form was used to gather relevant data. The collected data were analyzed by SPSS Version 21, using Chi-square and Fisher’s exact tests. A P-value less than 0.05 was considered statistically significant.
Results: Among 97 patients evaluated in this study (including 29 patients in the non-exposed group), the adverse effects of BC were observed in all age groups. Most adverse effects were attributed to trastuzumab (37.50%; CI: 31.6-44) and bevacizumab (26.78%; CI: 20.9-31.8). The MoAbs were well tolerated by the patients, causing minimum adverse effects that were manageable by supportive therapy. Anemia was the most prevalent adverse effect. Evaluation of the null hypothesis indicated that the adverse effects of MoAbs depended on their amount and composition. The results of analysis using the Naranjo scale revealed that most of the adverse effects were probable (67%) and possible (32%), respectively. Also, according to the WHO scale, most of the adverse effects were under the categories of probable (61.20%) and possible (38.14%), respectively.
Conclusion: Based on the present results, the adverse effects of MoAbs were manageable by supportive care. Anemia was found to be the most prevalent adverse effect. Meanwhile, no potential adverse cardiovascular event was observed in patients on trastuzumab, except one case of dilated cardiomyopathy.

Full-Text [PDF 378 kb]   (1644 Downloads) |   |   Full-Text (HTML)  (407 Views)  

 Based on the present results, the adverse effects of MoAbs were manageable by supportive care. Anemia was found to be the most prevalent adverse effect. Meanwhile, no potential adverse cardiovascular event was observed in patients on trastuzumab, except one case of dilated cardiomyopathy.


Type of Study: Original Article | Subject: Clinical medicine
Received: 2022/07/8 | Accepted: 2023/02/2 | Published: 2023/06/26

References
1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020;8(2):e191-e203. [DOI:10.1016/S2214-109X(19)30482-6] [PMID]
2. Smith BD, Jiang J, McLaughlin SS, et al. Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol. 2011;29(35):4647-53. [DOI:10.1200/JCO.2011.35.8408] [PMID]
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Eng J Med. 2001;344(11):783-92. [DOI:10.1056/NEJM200103153441101] [PMID]
4. Lutrino ES, Orlando L, Febbraro A, et al. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori J. 2020;106(4):301-5. [DOI:10.1177/0300891619887225] [PMID] [PMCID]
5. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The lancet Oncol. 2012;13(1):25-32. [DOI:10.1016/S1470-2045(11)70336-9] [PMID]
6. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Eng J Med. 2012;367(19):1783-91. [DOI:10.1056/NEJMoa1209124] [PMID] [PMCID]
7. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol; 1999;26(4 suppl 12):71-7
8. Slamon D,Leyland Jose B,Shak S,Leyland Jone B. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol.1998;17:98
9. Lima Cavalcanti ID, Silveira Cabral AG, dos Santos RJ. Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer. 2017. [DOI:10.30827/ars.v58i4.6766]
10. Huszno J, Leś D, Sarzyczny-Słota D, Nowara E. Cardiac side effects of trastuzumab in breast cancer patients-single centere experiences. Contemp Oncol (Pozn). 2013;17(2):190-5. [DOI:10.5114/wo.2013.34624] [PMID] [PMCID]
11. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16(8):2659-71. [DOI:10.1200/JCO.1998.16.8.2659] [PMID]
12. Kosalka P, Johnson C, Turek M, et al. Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. Curr Oncol. 2019;26(3):314-21. [DOI:10.3747/co.26.4823] [PMID] [PMCID]
13. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am College Cardiol. 2012;60(24):2504-12. [DOI:10.1016/j.jacc.2012.07.068] [PMID]
14. Anastasilakis AD, Toulis K, Goulis D, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Hormone Metab Res. 2009;41(10):721-9. [DOI:10.1055/s-0029-1224109] [PMID]
15. Hussain N, Said AS, Khan Z. Safety assessment of neoadjuvant pertuzumab combined with trastuzumab in nonmetastatic HER2-positive breast cancer in postmenopausal elderly women of South Asia. Int J Breast Cancer. 2018;2018. [DOI:10.1155/2018/6106041] [PMID] [PMCID]
16. Esin E, Oksuzoglu OBC, Erdur E, et al. Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer. J Oncol Sci. 2018;4(1):11-4. [DOI:10.1016/j.jons.2017.12.002]
17. Kistler A. Cardiotoxicity associated with monoclonal antibody chemotherapy. 2014.

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb